RhumbLine Advisers
RYTM icon

RhumbLine Advisers’s Rhythm Pharmaceuticals RYTM Stock Holding History

RhumbLine Advisers’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.08M Sell
69,858
-1,354
-2% -$132K 0.01% 1300
2025
Q4 		$7.62M Sell
71,212
-10,856
-13% -$1.15M 0.01% 1189
2025
Q3 		$8.29M Sell
82,068
-5,458
-6% -$507K 0.01% 1171
2025
Q2 		$5.53M Buy
87,526
+1,807
+2% +$111K ﹤0.01% 1351
2025
Q1 		$4.54M Buy
85,719
+2,988
+4% +$166K ﹤0.01% 1406
2024
Q4 		$4.63M Buy
82,731
+2,017
+2% +$111K ﹤0.01% 1458
2024
Q3 		$4.23M Sell
80,714
-2,349
-3% -$113K ﹤0.01% 1519
2024
Q2 		$3.41M Buy
83,063
+6,339
+8% +$253K ﹤0.01% 1610
2024
Q1 		$3.32M Buy
76,724
+3,552
+5% +$155K ﹤0.01% 1632
2023
Q4 		$3.36M Sell
73,172
-287
-0.4% -$9.05K ﹤0.01% 1636
2023
Q3 		$1.68M Buy
73,459
+3,861
+6% +$86.5K ﹤0.01% 1940
2023
Q2 		$1.15M Buy
+69,598
New +$1.26M ﹤0.01% 2215
2022
Q2 		– Sell
-56,942
Closed -$656K – 3218
2022
Q1 		$656K Sell
56,942
-3,595
-6% -$31.6K ﹤0.01% 2298
2021
Q4 		$604K Sell
60,537
-750
-1% -$8.43K ﹤0.01% 2432
2021
Q3 		$800K Buy
61,287
+275
+0.5% +$4.2K ﹤0.01% 2336
2021
Q2 		$1.2M Buy
61,012
+20,857
+52% +$433K ﹤0.01% 2166
2021
Q1 		$854K Sell
40,155
-1,423
-3% -$41.3K ﹤0.01% 2257
2020
Q4 		$1.24M Buy
41,578
+2,865
+7% +$72.8K ﹤0.01% 2046
2020
Q3 		$839K Sell
38,713
-5,915
-13% -$136K ﹤0.01% 2062
2020
Q2 		$995K Buy
44,628
+10,124
+29% +$197K ﹤0.01% 2048
2020
Q1 		$525K Buy
34,504
+2,109
+7% +$37.8K ﹤0.01% 2145
2019
Q4 		$744K Buy
32,395
+6,542
+25% +$145K ﹤0.01% 2209
2019
Q3 		$558K Sell
25,853
-240
-0.9% -$5.15K ﹤0.01% 2277
2019
Q2 		$574K Buy
26,093
+6,490
+33% +$164K ﹤0.01% 2306
2019
Q1 		$537K Buy
19,603
+50
+0.3% +$1.44K ﹤0.01% 2306
2018
Q4 		$526K Buy
19,553
+7,458
+62% +$206K ﹤0.01% 2278
2018
Q3 		$353K Buy
12,095
+661
+6% +$20.9K ﹤0.01% 2431
2018
Q2 		$357K Buy
+11,434
New +$313K ﹤0.01% 2454

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

RhumbLine Advisers's RYTM Position: Q1 2026 in Review

RhumbLine Advisers reduced its Rhythm Pharmaceuticals (RYTM) stake by 1.9% in Q1 2026, selling an estimated $132K and leaving 69,858 shares worth $6.08M. The position accounts for 0.01% of the portfolio, ranked #1300.

RhumbLine Advisers first reported a position in RYTM in Q2 2018 and has held it in 28 quarters since. The position peaked at $8.29M in Q3 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • RhumbLine Advisers held 69,858 shares of Rhythm Pharmaceuticals worth $6.08M as of Q1 2026.
  • RhumbLine Advisers sold 1,354 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $132K.
  • Rhythm Pharmaceuticals made up 0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #1300 holding.
  • RhumbLine Advisers first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 28 quarters since.
  • RhumbLine Advisers's Rhythm Pharmaceuticals position peaked at $8.29M in Q3 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.